Research Halted on ImmusanT Celiac Disease Vaccine
- healio.com 1
ImmusanT announced that it will discontinue its phase 2 global study of Nexvax2, a peptide-based immunomodulatory vaccine intended to treat celiac disease, according to a company press release.
Although Nexvax2 has been found to be safe and well-tolerated, an interim analysis demonstrated that the vaccine did not provide statistically meaningful protection from gluten exposure for patients with celiac disease compared with placebo.
When reached for comment, ImmusanT said that it “is continuing to compile and analyze information regarding the outcome of this study and will be providing an update accordingly.”
**************
ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based immunomodulatory vaccine therapies to patients with autoimmune diseases, has discontinued the Phase 2 global study for its lead candidate, Nexvax2®, intended as a treatment for celiac disease.
- Globe Newswire 2
The results from an interim analysis revealed Nexvax2 did not provide statistically meaningful protection from gluten exposure for celiac disease patients when compared with placebo.
Similar to earlier Phase 1 results, Nexvax2 was found to be safe and generally well tolerated. There were no concerning safety issues identified during the study.
ImmusanT will be actively investigating data gathered from the trial to further understand this outcome. The company will provide further information once available.
